All Clarivate websites use cookies to improve your online experience. They are already placed on your computer when you launch this website. You can change the cookie settings through your browser.

More information about our cookie policy.

Subscribe to BioWorld™ News Service

Although the end point was reached in the phase III study of pegzilarginase for the treatment of arginase 1 deficiency, the stock price of Aeglea Biotherapeutics Inc. still struggled at midday (NASDAQ: AGLE) plummeted 33%. The study reached its primary endpoint. After 24 weeks of treatment with pegylation, plasma arginine was significantly lower than baseline (p<0.0001). The data also showed a continuous decrease in plasma arginine and a positive trend in the measurement of gross motor function in Part E, which is an assessment of participants' mobility, including the ability to walk, run, and jump. Pegzilarginase is a recombinant human enzyme used to degrade arginine.

Milan-based Recordati SpA proposed to acquire Eusa Pharma Ltd., a global specialty pharmaceutical company, for approximately 724 million euros (US$817.5 million), deducting approximately 26 million euros of debt held by Eusa on June 30. The transaction “represents an excellent opportunity for further expansion and strengthens our product portfolio in new and underserved therapeutic areas, rare and niche oncology, and products with high potential for growth, and will provide potential further opportunities in these areas in the future. Expansion provides a platform," said Andrea Recordati, Chairman of Recordati. The completion of the transaction is subject to regulatory approval and is expected to be completed in the first half of 2022.

Isofol Medical AB’s stock price fell by as much as 31% on December 6th as the company notified investors that its ongoing phase III trial of afotisol for the treatment of metastatic colorectal cancer would not be able to prove statistically significant progress. The number of scheduled events required to have a significant impact-no survival (PFS) is based on the current statistical plan of the study. Isofol CEO Ulf Jungnelius described this issue as a "statistical storm in a teacup", but some investors apparently hold a different view. The Gothenburg, Sweden-based company said it may delay reporting top-line data from Agent’s head-to-head study, which compared arfolitixorin plus standard treatment with leucovorin plus standard treatment for unresectable first-line patients.

Chinese pharmaceutical companies will reduce the prices of more than five drugs by an average of 61.7% to make them enter the latest version of the National Drug Reimbursement List (NDRL). The National Medical Insurance Administration released a new catalog on December 3, 2021. The new catalog includes 74 new drugs, most of which are branded products without generic drugs in China. The 2021 NDRL includes 1,486 medicines, 1,374 Chinese medicines and 892 Chinese medicine products, all of which can be reimbursed.

The FDA’s December 8th meeting of its Cardiovascular and Renal Drug Advisory Committee triggered a large number of transactions, and the share price of Reata Pharmaceuticals Inc. (NASDAQ: RETA) of Plano, Texas fell 38%. After closing at $78.69 on Friday, Reata fell to a low of $48.40 on Monday and then recovered some of its losses. The documents that triggered the fall focused on Reata's bardoxolone methyl, an oral Nrf2 activator under FDA review to slow the progression of chronic kidney disease caused by Alport syndrome (AS). Although Reata's phase III trial reached its endpoint, "the FDA review team does not believe that the submitted data show that bardoxolone can effectively slow the loss of renal function in patients with AS and reduce the risk of progression to renal failure," the document.

LONDON-New research shows the extent to which an individual’s immune response to the SARS-CoV-2 virus is affected by the variants they were initially exposed to. This finding is important for updating vaccines against emerging and interesting variants. The attempt had an impact. Rosemary Bolton, Professor of Immunology and Respiratory Medicine at Imperial College London, said: "Exposure to different spike proteins will result in a reduced or enhanced response to further variants." "This is important for future-oriented vaccine design and dosage strategies. Meaning," she said.

BeiGene's Sylvant (Cetuximab for Injection) has been approved by China's NMPA for the treatment of patients with multicenter Castleman disease (MCD), including HIV negative and human herpes virus 8 (HHV-8) Negative patients. The Beijing-based company is preparing for a US$3.5 billion listing on the Shanghai Science and Technology Innovation Board, which is its third listing.

A far cry from the spectacle of Groundhog Day with amyloid-targeting antibodies that have had little effect on patients in trial after trial, researchers report that they succeeded in reducing Alzheimer’s disease (AD) in unexpected ways. ) risks of. Researchers at the Cleveland Clinic Foundation found that taking a Viagra prescription can reduce the risk of being diagnosed with AD by approximately 70%. Researchers from the University of Washington report that in a prospective adult thought change study, this is a long-term study on the risk and protective factors of dementia. People who have undergone cataract surgery have a 30% reduction in the risk of AD. This effect It lasted 10 years after the operation.

Abbvie, Abcellera, Abionyx, Acurx, Adagene, Adicet, Aeglea, Alpha Cognition, Amydis, Aqilion, Atamyo, Bavarian Nordic, Bayer, Bellicum, Benevolentai, Biofrontera, Biohaven, Bioplus, Bolt, Bsense, Camp4, Carisma, Catalyst, Cyxone, Cyrus, Eli Lilly, Fulcrum, Galderma, Gb Sciences, Greenlight, Gritstone, Glyco, Hummingbird, Hutchmed, Immunocore, Inflammasome, IO Biotech, Isofol, Jacobio, Johnson & Johnson, Junshi, Kaleido, Karyopharm, Kazia, Kolon Tissuegene, Kronos, Legend, Longeveron, Mediwound, Merck, Merus, Mesoblast, Neurona, NGM, Nrx, Ocular, Odyssey, Okyo, Open Orphan, PDC*Line, PDS, Pfizer, Phylex, Poolbeg, Pulmocide, Quantum Genomics, Rarestone, RDIF, Recursion, Redhill, Respirerx, Rhythm, Roche, Sapience, Scilex, SCynexis, Secura, Sinovac, SK Life Science, Sorrento, Spago, Spectrum, Springworks, Stoke, Surface Oncology, Trince, Valneva, Ventyx, Viacyte, Xenon, XNK, ZZ Biological Technology

The articles in this episode come from BioWorld's ongoing report on the COVID-19 coronavirus outbreak. Please note that we have added three key tables, they are...

Enjoy extended coverage of the most complete market view of BioWorld, BioWorld MedTech and BioWorld Asia with a single, easy-to-access subscription.

Copyright ©2021. all rights reserved. Design, CMS, hosting and web development :: electronic publishing